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Law Helps Ensure Safety of the Supply Chain

Pharmacy Health-System Managers Should Understand the Key
Components of the Drug Quality and Security Act
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HE DRUG QUALITY and Security Act

was signed into law on November 27,
2013, and included the Title 2 Drug
Supply Chain and Security Act (DSCSA). 1
This legislation was introduced to enact
a federal prescription drug safety standard
to decrease contamination, counterfeiting,
diversion, and otherwise harmful illicit
activities. It also improves the detection
and elimination of potentially unsafe
drugs from the drug supply chain to
protect US consumers.
DSCSA required that several key initiatives be implemented and maintained to
ensure supply chain safety. These have
included building an interoperable system
for the handling of suspected counterfeit
products and product serialization, tracing,
and verification. Components of this
regulation have been phased in over time,
and manufacturers and suppliers have spent
unspecified funds relabeling, retooling,
and working on the supply chain with the
ultimate goal of unit-level traceability by
November 27, 2023. 2-4
DSCSA was broad in scope, encompassing
prescription drugs in finished form for administration (capsules, tablets, and lyophilized
powder for reconstitution). It does not cover,
or exempts, several items that are difficult to
monitor, including blood or blood components for transfusion; compounded, homeopathic, and imaging drugs; intravenous and
OTC products; medical gases; and radioactive
biologics and drugs.
Critical components of DSCSA that
pharmacists need to know and continuously
monitor include the following:
• P roduct tracing. Supply chain
participants have been required to

electronically share product transaction
history with the next member of the
chain (interoperable data) until the
member is providing the medication
to the final user. 2 This part often has
included significant documentation
if the pharmacies are transferring
medication between 2 locations. This
can now be done electronically. Also,
DSCSA required that the transaction,
history, information, and statement be
provided upon a change of ownership
between trading partners. 1 Therefore,
if pharmacies loan products between
pharmacies under different ownership,
they would be accountable to provide
the statements to the entity
where the product is loaned and maintain records for 6 years. Exceptions
include distribution among hospitals
under common control, intracompany
distributions, and public health emergencies dispensed under a prescription. 1
•S
 erialization. For serialization, a
unique serial number is added to each
saleable unit of each prescription
product, which has been linked to the
information about the product’s batch
number, expiration date, and origin.
This process allows end-to-end tracing
and gives businesses the ability to
manage and track many transactions
and large data sets between trading
partners. The key for pharmacies is that
these systems are interoperable. 4
•S
 uspect product. This is a product
for which there is reason to think that
it appears unfit for distribution because
it could result in serious adverse health
consequences or death or it is poten-
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tially counterfeit, diverted, stolen, or
the subject of a fraudulent transaction.
In case of any of these events, the pharmacy will need policies and procedures
in place and a segregated area to store
the product until a resolution is found. 4
• Transaction history. This is a statement in electronic or paper form,
including the information for each
prior transaction going back to the
product manufacturer.
•T
 ransaction information. This
includes the names and addresses of the
businesses from which and to which
ownership was transferred, dosage
form, established or proprietary name of
a product, lot size, National Drug Code
container size, number of containers,
product strength, and shipment and
transaction dates.
•T
 ransaction statement. This is a
document or electronic statement
showing that the entity transferring
ownership in a transaction did not
deliberately provide false transaction
information, knowingly alter the
transaction history, or intentionally
ship an illegitimate or suspect product;
had processes and systems in place to
comply with verification requirements
under the law; received the product
from an individual authorized as
required under DSCSA; and received
transaction information and a statement
from the prior owner of the product, as
mandatory under the law.
•V
 erification. In the event of a
suspect product inquiry, supply chain
companies must be able to produce
relevant transaction documentation
within 24 hours (dispensers have 48

hours). Businesses need a storage and
retrieval system that quickly supports
these queries. The verification process
requires a system be put into place to
allow for the quarantine and investigation of suspect products and a mechanism to notify the FDA and trading
partners if an illegitimate product
is found. 5

Conclusion

DSCSA was enacted and phased in over the
past several years with the intent to help
secure the pharmaceutical supply chain.
Pharmacy health-system managers should
continue to work with FDA-approved
partners to analyze their data requirements, operations, and technology and to
understand their responsibilities around
tracking and tracing. ■
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